Opinion

Video

Treatment of COPD Based on Symptoms

Panelists discuss how chronic obstructive pulmonary disease (COPD) management follows a stepwise approach, beginning with bronchodilators (typically short-acting β2-agonists/long-acting β2-agonists) and progressing to combination therapy with long-acting muscarinic antagonists/inhaled corticosteroids based on symptom severity. Current unmet needs include more targeted anti-inflammatory treatments, better biomarkers for phenotyping, and therapies to halt disease progression, particularly for those who don’t respond well to conventional treatments.

Video content above is prompted by the following:

  • What is the typical treatment progression in symptomatic COPD?
  • Explain the role of inflammation and discuss the percentage of patients with COPD who have type 2 inflammation.
  • What are some of the unmet needs in the treatment of COPD?
Related Videos
Achieving Complete Renal Response and Reducing Corticosteroid Use in Lupus Nephritis Treatment With Obinutuzmab, with Richard Furie, MD
Aflibercept 8 mg Shows Durability at 3 Years in Wet AMD with W. Lloyd Clark, MD | Image Credit: Palmetto Retinal Center
Investigating Brensocatib, Potential First Treatment for Bronchiectasis, with James Chalmers, MBChB, PhD
Aflibercept 8 mg Noninferior for RVO in QUASAR with W. Lloyd Clark, MD | Image Credit: Palmetto Retinal Center
AI in Dermatology: Emerging Insights and Diverging Perspectives
© 2025 MJH Life Sciences

All rights reserved.